Study identifier:D3690C00005
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A double-blind, randomised, cross-over, placebo-controlled study of repeated oral doses of AZD3480 and a single dose of donepezil to evaluate the pharmacokinetic interaction between AZD3480 and donepezil in healthy extensive and poor metabolisers of CYP2D6
Alzheimer's disease
Phase 1
Yes
AZD3480, Donepezil
All
33
Interventional
20 Years - 60 Years
Allocation: Randomized
Endpoint Classification: Pharmacokinetics Study
Intervention Model: Crossover Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verified 01 Aug 2014 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The aims of this study are to 1) examine the effects of AZD3480 and donepezil on the blood concentrations of each other and 2) assess the safety and tolerability of the combined administration of AZD3480 with donepezil.
Location
Location
Manchester, United Kingdom
Arms | Assigned Interventions |
---|---|
Experimental: A AZD3480 + Donepezil | Drug: AZD3480 18 total doses of 40 mg, on days 1-18 Drug: Donepezil One single dose of mg on day 5 |
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.